1) Sugiyama T, Kamura T, Kigawa J, et al : Clinical characteristics of clear cell carcinoma of the ovary : a distinct histologic type with poor prognosis and resistance to platinum─based chemotherapy. Cancer 88 : 2584─2589, 2000
2) Goff BA, Sainz de la Cuesta R, Muntz HG, et al : Clear cell carcinoma of the ovary : a distinct histologic type with poor prognosis and resistance to platinum─based chemotherapy in stageIII disease. Gynecol Oncol 60 : 412─417, 1996
3) Ueno Y, Enomoto T, Otsuki Y, et al : Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin. Cancer Lett 241 : 289─300, 2006
4) Shimizu Y, Umezawa S, and Hasumi K : A phase IIstudy of combined CPT─11 and mitomycin─C in platinum refractory clear cell and mucinous ovarian carcinoma. Ann Acad Med Singapore 27 : 650─656, 1998
5) Kita T, Kikuchi Y, Kudoh K, et al : Exploratory study of effective chemotherapy to clear cell carcinoma of the ovary. Oncol Rep 7 : 327─331, 2000
6) Adachi S, Ogasawara T, Yamasaki N, et al : A pilot study of CPT─11 and cisplatin for ovarian clear cell adenocarcinoma. Jpn J Clin Oncol 29 : 434─437, 1999
7) Sugiyama T, Yakushiji M, Kamura T, et al : Irinotecan(CPT─11)and cisplatin as first─line chemotherapy for advanced ovarian cancer. Oncology 63 : 16─22, 2002
8) Matsumoto K, Katsumata N, Yamanaka Y, et al : The safety and efficacy of the weekly dosing of irinotecan for platinum─ and taxanes─resistant epithelial ovarian cancer. Gynecol Oncol 100 : 412─416, 2006
9) Komiyama S, Tsuji H, Asai S, et al : A pilot study of weekly docetaxel therapy for recurrent ovarian cancer, tubal cancer, and primary peritoneal cancer. Eur J Gynaecol Oncol 26 : 299─302, 2005